NEW YORK, April 14, 2005 (PRIMEZONE) -- Advanced Plant Pharmaceuticals, Inc. (OTCBB:APPI) and its majority owned subsidiary, Mazal Plant Pharmaceuticals Inc., announced today that Mazal has filed an Investigational New Drug Application (IND) with the United States Food and Drug Administration (FDA) for approval to begin Phase I/II clinical trials of MAHDL01, a pharmaceutical for modifying cholesterol in hypercholesterolemic patients.
Dr. Kanovsky, President of Mazal Plant Pharmaceuticals, said, "Since joining Mazal Plant Pharmaceuticals, our first objective has been the Clinical development of Mazal's cholesterol drug formula into a targeted cholesterol-modifying drug. It is gratifying that we have taken our first step in progressing towards this goal. We are hopeful that our application to the FDA will be met with the approval to proceed to human clinical trials at the Phase I/II stage."
Mr. David Lieberman, CEO of Advanced Plant Pharmaceuticals, said, "With our significant majority interest in Mazal Plant Pharmaceuticals, we are excited by the progress Mazal has made in advancing MAHDL01 towards this important benchmark necessary for our goal in introducing a new drug to the marketplace."
About Advanced Plant Pharmaceuticals, Inc.
Advanced Plant Pharmaceuticals, Inc. (APPI) focuses on the research and development of whole plant-based products. APPI has a composition-oriented patent for a proprietary process of utilizing whole plants to manufacture more efficacious all-natural nutritional supplements. For more information, visit the Company's Corporate website: http://www.advancedplantpharm.com
About Mazal Pharmaceuticals, Inc.
Mazal Pharmaceuticals is focused on developing a treatment of hypercholesterolemia / lipidemia. Mazal Plant Pharmaceuticals is an innovator of whole plant pharmaceuticals focused on the utilization of whole plants in the development of healthier pharmaceutical drugs for the treatment of human diseases. Corporate website: http://www.mazal.cc
Forward-Looking Statements:
This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company.